Foundation Medicine Inc (NASDAQ:FMI) SVP Robert W. Hesslein sold 18,021 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $64.30, for a total transaction of $1,158,750.30. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Robert W. Hesslein also recently made the following trade(s):
- On Tuesday, January 2nd, Robert W. Hesslein sold 1,864 shares of Foundation Medicine stock. The shares were sold at an average price of $64.00, for a total transaction of $119,296.00.
Shares of Foundation Medicine Inc (FMI) traded down $0.60 during trading hours on Friday, hitting $66.35. 89,600 shares of the stock were exchanged, compared to its average volume of 289,267. The firm has a market cap of $2,410.00, a price-to-earnings ratio of -14.84 and a beta of -0.01. Foundation Medicine Inc has a 12 month low of $17.50 and a 12 month high of $74.30. The company has a current ratio of 2.24, a quick ratio of 2.03 and a debt-to-equity ratio of 0.47.
Foundation Medicine (NASDAQ:FMI) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. The company had revenue of $42.66 million during the quarter, compared to analyst estimates of $37.99 million. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. The business’s revenue for the quarter was up 45.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.90) EPS. equities analysts forecast that Foundation Medicine Inc will post -4.44 earnings per share for the current fiscal year.
FMI has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Foundation Medicine from a “hold” rating to a “buy” rating and set a $59.00 target price for the company in a research note on Monday, November 6th. BidaskClub raised shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $45.33.
Large investors have recently modified their holdings of the company. Legal & General Group Plc lifted its stake in shares of Foundation Medicine by 8.6% in the 2nd quarter. Legal & General Group Plc now owns 3,442 shares of the company’s stock worth $138,000 after acquiring an additional 274 shares during the period. SG Americas Securities LLC lifted its stake in shares of Foundation Medicine by 36.6% in the 3rd quarter. SG Americas Securities LLC now owns 6,481 shares of the company’s stock worth $261,000 after acquiring an additional 1,736 shares during the period. Voya Investment Management LLC acquired a new stake in shares of Foundation Medicine in the 2nd quarter worth approximately $262,000. Creative Planning acquired a new stake in shares of Foundation Medicine in the 4th quarter worth approximately $599,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Foundation Medicine by 419.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,578 shares of the company’s stock worth $385,000 after acquiring an additional 7,735 shares during the period. 32.68% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/19/foundation-medicine-inc-fmi-svp-robert-w-hesslein-sells-18021-shares.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.